An Australian stem cell and regenerative medicine company

June 25, 2018

Shaw and Partners Research Update: “Highly Encouraging Safety and Efficacy Data Further De-risks Cynata“

View Report

View the latest Shaw & Partners Research Update for Cynata Therapeutics

June 25, 2018

NDF’s Stuart Roberts Updates Cynata Research Coverage

View Report

View the latest update from NDF on Cynata Therapeutics

April 05, 2018

FDA Grants CYP-001 Orphan Drug Designation; Reiterate Buy

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation.

March 11, 2018

Shaw and Partners Research Update: "1H18 Produced a De Risking and Increased Investor Interest"

View Report

Shaw and Partners forecasts and 12 month TP have been revised (TP increases to $1.95 from $1.20). Our recommendation remains unchanged. BUY.

March 01, 2018

H.C. Wainwright & Co. Research Update: “Cohort A Primary Evaluation Period Data Comes up Trumps; Reiterate Buy”

View Report

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation and price target of $1.50